Oxford Bioscience Partners and Merlin Nexus joined Novo Nordisk in pumping $15 million more into Xencor's Series E, bringing the grand total to $60 million. Xencor is developing new therapies for Hodgkin's disease, T-cell lymphoma, cancer and inflammatory diseases. To date, Xencor has raised $142 million for its pipeline work. Xencor was a 2005 Fierce 15Â company.
- check out Xencor's release on the round
- see the report from SoCalTech
Related Article:
Xencor pockets $45M in new funding round. Report